Avatrombopag for chemotherapy induced thrombocytopenia in patients with nonhaematological cancers
Avatrombopag is administered orally. It works by attaching to a hormone called thrombopoietin, which stimulates the production of platelets by attaching to receptors (targets) in the bone marrow and helping in increasing the platelet count. Avatrombopag does not interact with polyvalent cations (calcium, magnesium, iron, selenium, zinc, etc.) in foods, mineral supplements, or antacids that could reduce systemic exposure and efficacy. If licensed, avatrombopag will provide a treatment option for CIT in patients with active non-haematological cancers.
LN-145 for recurrent, metastatic or persistent cervical carcinoma
LN-145 is composed of T-cells (a type of immune cell) that are collected from the patient and grown to large numbers in the laboratory. They are then administered intravenously into the patient alongside IL-2 (a protein that activates T-cells), in order to encourage them to recognise and destroy the tumour. Therefore, if licensed, LN-145 would offer an additional treatment option to patients with recurrent, metastatic or persistent cervical cancer, who currently have limited treatment options.
Daratumumab in addition to bortezomib, lenalidomide and dexamethasone for multiple myeloma – first line
Daratumumab is a type of immune therapy that is administered subcutaneously and acts by inhibiting the growth of cancer cells in MM via a surface protein called CD38. If licenced it is hoped daratumumab in addition to bortezomib, lenalidomide and dexamethasone could provide better long term outcomes for patients with newly diagnosed multiple myeloma who are ineligible for high-dose chemotherapy with autologous stem cell transplant.
Cemiplimab as a monotherapy for advanced or metastatic non-small-cell lung cancer whose tumours express PD-L1 – first line
Cemiplimab is a type of protein called an antibody, which can bind to PD-1 and prevent it interacting with PD-L1. Therefore, it allows the T-cells to attack the cancer cells. Cemiplimab is administered by intravenous infusion. The results from clinical trials have suggested that intravenous administration of cemiplimab increases overall survival in individuals with advanced/metastatic NSCLC who are positive for PD-L1. Therefore, if licensed, cemiplimab would offer an additional treatment option for patients with advanced/metastatic PD-L1 positive NSCLC.
177Lu-PSMA-617 for metastatic castrationresistant prostate cancer – third line
177Lu-PSMA-617 delivered via intravenous infusion. It works by releasing an energetic beta particle to precisely deliver cell-killing radiation to the site of disease to kill cancer cells. Earlier studies indicate that 177Lu-PSMA-617 may demonstrate clinical benefit in patients with mCRPC in the third-line setting, where patients have no clear standard of care, having exhausted all key treatment options. If licensed, 177LuPSMA-617 will provide a treatment option for patients in this setting.
Enfortumab vedotin for locally advanced or metastatic urothelial cancer
Enfortumab vedotin is an antibody-drug conjugate that is administered intravenously. It works by selectively targeting the protein Nectin-4 which is found in high quantities in the cells of bladder cancer patients. When Enfortumab vedotin attaches to Nectin4 it causes the release of an anticancer agent, resulting in cancer cell death. Enfortumab vedotin has been demonstrated to be safe and efficacious in earlier clinical studies. If licensed, it may provide a treatment option for patients with advanced or metastatic urothelial cancer whose disease has progressed after being previously treated with chemotherapy and immunotherapy.
Palbociclib for breast cancer – post neoadjuvant therapy
Palbociclib is an oral cancer medicine. It works by blocking the activity of certain enzymes known as cyclin-dependant kinases (CDK) 4 and 6, which play a key role in regulating the way cells grow and divide. By blocking these enzymes, palbociclib slows the growth of breast cancer cells, and has been shown to be tolerable to patients over an extended period of time. If licenced, palbociclib will provide an additional treatment option for adults with invasive early breast cancer.
Oportuzumab monatox for non-muscle invasive bladder cancer – second line
Oportuzumab monatox is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC), specifically high-grade (Ta or any T1) papillary disease who were unresponsive to prior treatment with Bacillus CalmetteGuerin (BCG) with or without interferon. Bladder cancer starts in the inner lining of the bladder and the most common symptom is …
Nivolumab in combination with ipilimumab for previously untreated unresectable or metastatic urothelial cancer – first-line
Nivolumab in combination with ipilimumab is in clinical development for PD-L1 positive patients with previously untreated unresectable or metastatic urothelial cancer regardless of cisplatin eligibility. Urothelial cancer, a subset of bladder cancer, occurs on the lining of the renal pelvis, ureter, bladder and urethra, and other parts of the urinary system. In some cases,the tumour spreads into the surrounding muscles or other parts of the body which means that it cannot be cured by surgery. Metastatic urothelial cancer occurs when the cancer has spread to other parts of the body, such as the liver or bones. The symptom of urothelial cancer is blood in the urine, but symptoms may only appear once the cancer grows larger or into the deeper layers of the bladder wall for both men and women. Other symptoms may include increased frequency/urgency/pain of urine passing, weight loss, back/lower tummy/bone pain, fatigue and illness.
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer
Tucatinib is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein. By inhibiting HER2, it is hoped tucatinib will inhibit the growth of HER2-positive tumours. If licenced, tucatinib in addition to trastuzumab and capecitabine will provide an additional treatment option for adults with advanced HER2 positive metastatic breast cancer.